The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing COPD and establish how the chronic lung disease progresses.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

From the company's own site, we can see this pharma brand has a diversified portfolio of therapies across multiple clinical ...

“The development of Muse, a result of our ongoing collaboration with OpenAI and Formation Bio, represents another proof point ...

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in ...